Why the study?
The real-world impact of switching to hs-cTn assays with sex-specific reference rates on patient outcomes and health service costs was poorly understood.
Does switching to high-sensitivity cardiac troponin assays reduce costs and MACE in patients presenting to the ED with suspected ACS?
Does switching to high-sensitivity cardiac troponin assays reduce costs and MACE in patients presenting to the ED with suspected ACS?
Transitioning to high-sensitivity troponin assays for suspected ACS in the ED is highly cost-effective and associated with reduced 12-month MACE, particularly in women.
Answers are grounded in this paper and cite their sources.
May not yet warrant practice change in EDs; leaves open randomized tests of hs-cTn cost-effectiveness.
BACKGROUND: Switching from conventional to high-sensitivity cardiac troponin (hs-cTn) assays with sex-specific reference rates for threshold troponin levels enables detection of smaller amounts of myocardial damage. However, the real-world impact of these assays on patient outcomes and health service costs is poorly understood. We investigated the cost-effectiveness of switching to hs-cTn assays for patients presenting to Australian Emergency Departments (EDs) with suspected acute coronary syndrome (ACS) with a 12-month follow-up period. METHODS: Using linked administrative data from 9 tertiary hospitals for patients aged 20 and above who presented to ED with suspected ACS between March 2011 and November 2015, we applied a difference-in-differences methodology to compare costs and major adverse cardiac events between hospitals switching to hs-cTn assays and hospitals continuing to use conventional assays. RESULTS: We identified 179,681 consecutive patients, of whom 87,019 presented during the preperiod and 92,662 the postperiod. Switching to hs-cTn was associated with a reduction in the cost of the index event (-$1,022, 95% CI: -$1,034, -$1,009), a reduction in total costs at 12 months (-$1,373, 95% CI: -$1,387, -$1,360) and a reduction in the percentage of patients experiencing a MACE outcome within 12-months (-0.55%, 95% CI: -0.88%, -0.21%). The reduction in MACE outcomes was larger for female patients (-1.17%, 95% CI: -1.19%, -1.14%) than for all patients and for males. CONCLUSIONS: The switch to hs-cTn is highly cost-effective across all patients and for each sex. The reduction in MACE outcomes and costs within 12 months are greater for females than for males.
No takes yet. Share an insight, caveat, or question.
Pincombe et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: